Tetrahydro-naphthalene derivatives as glucocorticoid receptor modulators
AssigneeGlaxo Group Limited
InventorsChristine Edwards, Garry Fenton, Simon John Fawcett MacDonald, Gordon Gad Weingarten
Life of this patent
Estimating the term…
Abstract
The present invention is directed to compounds of formula (I): wherein R represents a methyl or an ethyl group X represents N, C—H or C—CH3 when X represents C—H or C—CH3, Y represents N when X represents N, Y represents C—H and physiologically functional derivatives thereof, pharmaceutical compositions comprising the compounds, the use of the compounds for the manufacture of medicaments particularly for the treatment of inflammatory and/or allergic conditions, processes for the preparation of the compounds, and chemical intermediates in the processes for the manufacture of the compounds.
Claims20
A compound of formula (I):
- wherein
- R represents a methyl or an ethyl group
- X represents N, C—H or C—CH3 with the proviso that when X represents C—H or C—CH3, Y represents N and when X represents N, Y represents C—H
- or a physiologically functional compound thereof.
A compound of formula (I):
- wherein
- R represents a methyl or an ethyl group
- X represents N, C—H or C—CH3 with the proviso that when X represents C—H or C—C—H3, Y represents N and when X represents N, Y represents C—H.
A compound which is:
- 1,1,1-Trifluoro-3-(1-methyl-1,2,3,4-tetrahydro-1-naphthalenyl)-2-[(5-quinolinylamino)methyl]-2-propanol D1;
- 1,1,1-Trifluoro-3-[(2-methyl-5-quinolinyl)amino]-2-[(1-methyl-1,2,3,4-tetrahydro-1-naphthalenyl)methyl]-2-propanol D1;
- 1,1,1-Trifluoro-3-(5-isoquinolinylamino)-2-[(1-methyl-1,2,3,4-tetrahydro-1-naphthalenyl)methyl]-2-propanol D1;
- 3-(1-Ethyl-1,2,3,4-tetrahydro-1-naphthalenyl)-1,1,1-trifluoro-2-[(5-isoquinolinylamino)methyl]-2-propanol D1;
- 3-(1-Ethyl-1,2,3,4-tetrahydro-1-naphthalenyl)-1,1,1-trifluoro-2-{[(2-methyl-5-quinolinyl)amino]methyl}-2-propanol D1;
- 3-(1-Ethyl-1,2,3,4-tetrahydro-1-naphthalenyl)-1,1,1-trifluoro-2-{[(2-methyl-5-quinolinyl)amino]methyl}-2-propanol D1E1;
- 3-(1-Ethyl-1,2,3,4-tetrahydro-1-naphthalenyl)-1,1,1-trifluoro-2-[(5-quinolinylamino)methyl]-2-propanol D1;
- or
- a physiologically functional compound thereof.
A compound which is:
- 1,1,1-Trifluoro-3-(1-methyl-1,2,3,4-tetrahydro-1-naphthalenyl)-2-[(5-quinolinylamino)methyl]-2-propanol D1E1;
- 1,1,1-Trifluoro-3-[(2-methyl-5-quinolinyl)amino]-2-[(1-methyl-1,2,3,4-tetrahydro-1-naphthalenyl)methyl]-2-propanol D1E1;
- 1,1,1-Trifluoro-3-(5-isoquinolinylamino)-2-[(1-methyl-1,2,3,4-tetrahydro-1-naphthalenyl)methyl]-2-propanol D1E2;
- 3-(1-Ethyl-1,2,3,4-tetrahydro-1-naphthalenyl)-1,1,1-trifluoro-2-[(5-isoquinolinylamino)methyl]-2-propanol D1E2;
- 3-(1-Ethyl-1,2,3,4-tetrahydro-1-naphthalenyl)-1,1,1-trifluoro-2-{[(2-methyl-5-quinolinyl)amino]methyl}-2-propanol D1E1;
- or
- a physiologically functional compound derivative thereof.
A compound which is:
- 1,1,1-Trifluoro-3-[(2-methyl-5-quinolinyl)amino]-2-[(1-methyl-1,2,3,4-tetrahydro-1-naphthalenyl)methyl]-2-propanol D1E1;
- 1,1,1-Trifluoro-3-(5-isoquinolinylamino)-2-[(1-methyl-1,2,3,4-tetrahydro-1-naphthalenyl)methyl]-2-propanol D1E2;
- or
- a physiologically functional compound thereof.
Dependencies are inferred from the claim text.